Cargando…
Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds
The long-standing promise for the application of engineered T lymphocytes to target and eradicate malignancy has begun to be realized recently, with remarkable clinical success reported by a number of groups using Chimeric Antigen Receptor –engineered T cells to target CD19-positive hematologic mali...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754893/ https://www.ncbi.nlm.nih.gov/pubmed/26885367 http://dx.doi.org/10.1186/s40425-016-0108-2 |